End-tidal Carbon Monoxide Subjects
DeviceETCO monitor will be used to measure CO levels in subjects and controls.
NCT Number: NCT02530242
Modify the design of the CoSense device (Model C20112, currently cleared by the FDA for ETCO (end-tidal carbon monoxide) monitoring to improve accuracy and consistency under temperature conditions encountered in countries with high prevalence of SCD (Sickle Cell Disease).
Looking for future studies?
Notify Me1 year–18 year
All sexes
Interventional
Not applicable
Increase the temperature operating range of ETCO measurements to 5 to 45°C. The signal output-to-CO (carbon monoxide) concentration correlation of the CO sensor is dependent on temperature. The new algorithm will be a different approach because the current algorithm is at the limits of its capability. We will establish the new specifications by determining performance in a bench model under simulated temperature conditions. We will then determine the ability of the modified device to distinguish between SCD and healthy controls. During this initial testing, we will examine the validity of ETCO measurements under regulated room temperature in the hospital setting. We will enroll 20 subjects, 10 each in the SCD arm and control arm to determine the mean and variance of the ETCO values.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ETCO monitor will be used to measure CO levels in subjects and controls.
ETCO monitor will be used to measure CO levels in subjects and controls.
Time frame: 1 hour
Compare ETCO between subjects and controls
UCSF Benioff Children's Hospital Oakland
Other
Point-of-Care End-Tidal Carbon Monoxide Measurement to Screen for Sickle Cell Disease
Acronym: SCDCO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00011648
Anemia, Anemia, Hemolytic
Washington D.C., District of Columbia, United States
View Trial DetailsNCT04255875
Anemia, Anemia, Hemolytic
New Haven, Connecticut, United States
View Trial DetailsNCT01758042
AL Amyloidosis, Acute Lymphoblastic Leukemia (ALL)
Boston, Massachusetts, United States
View Trial DetailsNCT05169580
Anemia, Anemia, Hemolytic
Little Rock, Arkansas, United States
View Trial Details